Lipoprotein (a)

Elevated Lp(a) levels are associated with a significantly increased risk of cardiovascular disease, including heart attack, stroke, and progressive narrowing of arteries supplying vital organs.

Large population studies, including the Copenhagen Heart Study, have demonstrated that genetically elevated Lp(a) levels are causally linked to increased risk of myocardial infarction, independent of LDL cholesterol and other traditional risk factors. Because Lp(a) promotes both atherosclerosis and thrombosis, individuals with high levels may be at risk even when LDL-C is well controlled.

Elevated Lp(a) is best viewed as a lifelong, inherited risk marker, highlighting the need for aggressive management of all other modifiable cardiovascular risk factors.

Potential Treatment Considerations

For educational purposes only. Treatment decisions should be made by a qualified healthcare professional.

• Assess family history of cardiovascular disease

• Evaluate inflammatory and plaque-instability markers such as Lp-PLA₂ and MPO

  • Abnormal findings may indicate vulnerable plaque and elevated thrombotic risk

• Consider vascular imaging:

  • Carotid intima-media thickness (CIMT)

  • Coronary artery calcium (CAC) scoring

• Optimize control of all modifiable risk factors (LDL-C, blood pressure, glucose, inflammation)

• Antiplatelet therapy (e.g., aspirin or clopidogrel) may be considered in select high-risk individuals if not contraindicated

• Niacin therapy has historically been used to lower Lp(a), though its role should be carefully evaluated on an individual basis

Emerging therapies specifically targeting Lp(a) are currently under active clinical investigation.

Low Lp(a) levels—typically defined as <5 mg/dL (approximately the lowest 20% of the population)—are generally associated with a reduced risk of myocardial infarction, ischemic stroke, and aortic stenosis.

However, multiple prospective studies have observed an inverse relationship between Lp(a) concentration and type 2 diabetes risk. Very low Lp(a) levels (often <7 mg/dL) have been associated with a modestly increased prevalence of type 2 diabetes, though the mechanisms underlying this association are not fully understood.

Importantly, low Lp(a) is not considered pathological and does not require intervention. Interpretation should always be made in the context of overall metabolic and cardiovascular risk.

Lipoprotein(a), or Lp(a), is a cholesterol-rich lipoprotein that is an established, independent risk factor for cardiovascular and vascular disease. Lp(a) consists of an LDL (“bad cholesterol”) particle bound to a unique protein called apolipoprotein(a). Unlike most cholesterol markers, Lp(a) levels are largely genetically determined and are minimally influenced by diet, exercise, or lifestyle changes.

Elevated Lp(a) can promote plaque formation, inflammation, and thrombosis within blood vessels, increasing the risk of heart attack, stroke, and aortic valve disease—even when standard lipid levels appear normal.